07:30 ET

PROLOR Biotech to Present at 2012 Citi Global Health Care Conference

... ABOUT PROLOR PROLOR Biotech, Inc. is a clinical stage biopharmaceutical company applying unique technologies, including its patented CTP technology, primarily to develop longer-acting proprietary versions of already approved therapeutic proteins that currently generate billions of dollars in annual global sales.

07:00 ET

Shire Announces European Approval of Manufacturing Facility for VPRIV® (velaglucerase alfa)

The risks and uncertainties include, but are not limited to, risks associated with: the inherent uncertainty of research, development, approval, reimbursement, manufacturing and commercialization of Shire's Specialty Pharmaceuticals, Human Genetic Therapies and Regenerative Medicine products, as well as the ability to secure...

06:00 ET

Lexicon Pharmaceuticals Provides Clinical Pipeline Update and Reports 2011 Fourth Quarter and Full Year Financial Results

All forward-looking statements are based on management's current assumptions and expectations and involve risks, uncertainties and other important factors, specifically including those relating to Lexicon's ability to successfully conduct clinical development of LX1031, LX1032, LX1033, LX2931, LX4211 and LX7101 and preclinical...

Feb 21, 2012, 18:00 ET

Life Technologies to Present at Barclays Capital Global Healthcare Conference

CARLSBAD, Calif., Feb. 21, 2012... Life Technologies had sales of $3.7 billion in 2011, employs approximately 10,400 people, has a presence in approximately 160 countries, and possesses one of the largest intellectual property estates in the life sciences industry, with approximately 4,000 patents and exclusive licenses.

Feb 21, 2012, 07:00 ET

Soligenix Announces Positive Survival Results of SGX202 in Radiation Injury

Soligenix cannot assure you that it will be able to successfully develop or commercialize products based on its technology, including orBec®, SGX201, SGX202, SGX203, SGX204, RiVax™, ThermoVax™, and LPMTM, particularly in light of the significant uncertainty inherent in developing vaccines against bioterror threats,...

Feb 21, 2012, 06:00 ET

ChromaDex® Names Debra Heim as COO

The company has an expanding pipeline of new ingredients, including its pTeroPure® (http://www.pteropure.com) pterostilbene for which it has worldwide, exclusive patent pending rights.... In addition, forward-looking statements may also be adversely affected by general market factors, competitive product development,...

Feb 21, 2012, 04:00 ET

Inovio's Scientific Advisory Board Chairman Elected as a Fellow by the American Association for the Advancement of Science

Actual events or results may differ from the expectations set forth herein as a result of a number of factors, including uncertainties inherent in pre-clinical studies, clinical trials and product development programs (including, but not limited to, the fact that pre-clinical and clinical results referenced in this release may...

Feb 21, 2012, 01:00 ET

Sigma® Life Science Obtains Global License for Kyoto University's iPS Cell Patent Portfolio, Deepens Commitment to Drug Discovery and ADME/Toxicology

 Sigma-Aldrich Corporation (Nasdaq: SIAL) today announced that Sigma Life Science, its innovative biological products and services research business, has furthered its commitment to stem cell research, drug discovery and ADME/Toxicology by acquiring a worldwide license to use Kyoto...

Feb 17, 2012, 17:21 ET

ChromaDex® Announces Management Changes

The company has an expanding pipeline of new ingredients, including its pTeroPure® (www.pteropure.com) pterostilbene for which it has worldwide, exclusive patent pending rights.... In addition, forward-looking statements may also be adversely affected by general market factors, competitive product development, product...

Feb 17, 2012, 16:05 ET

Savient Pharmaceuticals to Present at the Citi 2012 Global Health Care Conference

MVP and Duke have been granted U.S. and foreign patents disclosing and claiming the licensed technology and, in addition, Savient owns or co-owns U.S. and foreign patents and patent applications, which collectively form a broad portfolio of patents covering the composition, manufacture and methods...

Feb 17, 2012, 06:00 ET

Improved Cord Blood Processing Research on BioLife Solutions CryoStor® Published in TRANSFUSION

 BioLife Solutions, Inc. (OTCBB: BLFS), a leading developer, manufacturer and marketer of proprietary clinical grade... About BioLife Solutions BioLife Solutions develops, manufactures and markets patented hypothermic storage and cryopreservation solutions for cells and tissues.

Feb 16, 2012, 18:31 ET

Lexicon to Report Fourth Quarter and Year End 2011 Financial Results on February 22, 2012

All forward-looking statements are based on management's current assumptions and expectations and involve risks, uncertainties and other important factors, specifically including those relating to Lexicon's ability to successfully conduct preclinical and clinical development of its potential drug candidates, advance additional...

Feb 16, 2012, 15:33 ET

GeneLink Biosciences Completes Sale of GeneWize Life Sciences

 GeneLink Biosciences, Inc. (OTCBB: GNLK), a leading consumer genomics biotech company, has completed the sale of the stock of its... GeneLink's patented technologies include proprietary DNA assessments linked to personalized health, beauty and wellness applications and products.

Feb 16, 2012, 14:48 ET

Receptos Scientists Publish Determination of a High Resolution Sphingosine 1-Phosphate Receptor 1 Structure in Science

Advancements in the technology, as well as in proprietary drug discovery and development programs at Receptos, have resulted in a patent estate comprising twelve patent applications, seven of which are directed to small molecule composition of matter and four of which support the technology platform, including...

Feb 16, 2012, 08:45 ET

BioDelivery Sciences Receives Patent Allowance Triggering $15 Million Milestone Payment from Endo Pharmaceuticals

(Nasdaq: BDSI) announced the U.S. Patent and Trademark Office (USPTO) has issued a Notice of Allowance of BDSI's patent application (No. 13/184306) that, once formally granted, will extend the exclusivity of the BioErodible MucoAdhesive (BEMA) drug delivery technology for BEMA Buprenorphine and BEMA...

Feb 16, 2012, 08:30 ET

Xenogenics Received Rights to Polyanhydride Compounds Drug Delivery Patent

(OTC Bulletin Board: MCET) has exclusive license rights to a polyanhydride compounds drug delivery patent recently granted in Canada. The patent was granted to Rutgers University this July for polyanhydrides which link low molecular weight drugs containing a carboxylic acid group and an amine, thiol, alcohol or...

Feb 16, 2012, 08:00 ET

Regulus Announces New Publication Showing Potential Therapeutic Benefit of Targeting microRNA-21 in Fibrosis

LA JOLLA, Calif.,... Regulus' intellectual property estate contains both the fundamental and core patents in the field and includes over 600 patents and more than 300 pending patent applications pertaining primarily to chemical modifications of oligonucleotides targeting microRNAs for therapeutic applications.

Feb 16, 2012, 04:30 ET

ResearchMoz: Vaccine Production Market (Trends, Techniques, Key Players, Spending Estimates and Forecasts)

Browse All  Vaccines  Market Reports & Industry Analysis Browse AllKalorama Information  Reports & Industry Analysis Browse All Vaccine Market Research Reports Vaccine Production Market Seasonal Influenza Vaccine Market Hepatitis B Vaccine Hepatitis B Vaccine - Comprehensive patent search Emerging Cancer...

Feb 15, 2012, 13:00 ET

IntegriChain Delivers Pharmacy Level Inventory Metrics

 IntegriChain Inc., a commercial provider of data and analytic insights to the pharmaceutical industry, announced today the introduction of a new... With blockbuster patent expirations and mounting supply shortages, retail inventory is key to sound business planning."

Feb 15, 2012, 07:30 ET

HypnoCore to Launch New Consumer Sleep Diagnostic Solution "SleepRate" at Mobile World Congress in Barcelona, February 27th, Hall 2.0, Booth 2C75

HypnoCore Ltd announced today that it will launch its flagship SleepRate product, a novel consumer sleep monitoring and management solution, at Mobile World in Barcelona, Spain,... SleepRate is based on HypnoCore's patented , FDA approved and CE cleared technology.